

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

**(1) CHANGE OF JOINT COMPANY SECRETARY, SECRETARY TO THE BOARD AND AUTHORIZED REPRESENTATIVE; AND
(2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

CHANGE OF JOINT COMPANY SECRETARY, SECRETARY TO THE BOARD AND AUTHORIZED REPRESENTATIVE

The board (the “**Board**”) of directors of Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) hereby announces that Ms. Chen Yingge (“**Ms. Chen**”) has tendered her resignation as joint company secretary, secretary to the Board and authorized representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 24 April 2024 due to career development reasons. Ms. Chen confirmed that she has no disagreement with the Board, and there are no matters in respect of her resignation that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

Mr. Wang Zhengyu (“**Mr. Wang**”) has been appointed as the joint company secretary, secretary to the Board and authorized representative of the Company under Rule 3.05 of the Listing Rules with effect from 24 April 2024 in replacement of Ms. Chen. Mr. Wang’s term of office as the secretary to the Board shall be consistent with the term of the third session of the Board.

The biography of Mr. Wang is as follows:

Mr. Wang Zhengyu (王征宇), aged 29, has been the securities affairs representative of the Company since March 2021 and is responsible for handling the legal and corporate governance matters of the Company. From May 2019 to March 2021, he served as the manager of the securities department of the Company. Mr. Wang has previously worked in the securities legal affairs department of Jiangsu Hengrui Medicine Co., Ltd.* (江蘇恒瑞醫藥股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600276). Mr. Wang graduated from Tongji University with Juris master and has obtained the national legal professional qualification and the qualification to serve as a secretary to the board of directors of a company listed on the STAR Market of the Shanghai Stock Exchange.

Although Mr. Wang does not currently possess the qualifications as set out in Rule 3.28 of the Listing Rules, the Company believes that Mr. Wang, by virtue of his knowledge and experience as well as his understanding of the business and operations of the Company, is capable of discharging his duties as a joint company secretary. As such, the Company believes that it would be in its best interests to have Mr. Wang as its joint company secretary. Ms. Lai Siu Kuen (“**Ms. Lai**”), the other joint company secretary of the Company, will assist Mr. Wang in discharging his duties as a joint company secretary.

Ms. Lai is a Director of Corporate Services of Tricor Services Limited, an Asia’s leading business expansion specialist specializing in integrated Business, Corporate and Investor Services. Ms. Lai has over 20 years of experience in the corporate secretarial field. She has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Lai is a Chartered Secretary and a Fellow of both The Hong Kong Institute of Chartered Secretaries and The Chartered Governance Institute.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Listing Rules, an issuer must appoint a company secretary who satisfies the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that an issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of a company secretary by virtue of his academic or professional qualifications or relevant experience.

Mr. Wang currently does not possess the qualifications of company secretary as required under Rule 3.28 of the Listing Rules. The Company has applied, and the Stock Exchange has granted, a waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the “**Waiver**”) with respect to the appointment of Mr. Wang for a period of three years from the date of the appointment of Mr. Wang (the “**Waiver Period**”) as the joint company secretary of the Company on the following conditions:

- (i) Mr. Wang must be assisted by Ms. Lai during the Waiver Period; and
- (ii) the Waiver could be revoked if there are material breaches of the Listing Rules by the Company.

Before the end of the Waiver Period, the Company must demonstrate and seek the confirmation from the Stock Exchange that Mr. Wang, having had the benefit of Ms. Lai’s assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The Stock Exchange may withdraw or change the Waiver if the Company’s situation changes.

The Board would like to take this opportunity to express its sincere gratitude to Ms. Chen for her contributions to the Company during her tenure of office and extend a warm welcome to Mr. Wang for his new appointment.

By order of the Board of
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 24 April 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Feng Hui and Mr. Tang Yi as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*